Skip to main content Skip to main navigation menu Skip to site footer
logo Mediterranean Journal of Hematology and Infectious Diseases

eISSN 2035-3006

  • Home
  • About the Journal
  • Editorial Board
  • Current
  • Archives
  • Announcements
  • Register
  • Login
  • Journal Statistics
  • Search
  • Contact
  • Announcements

Editor-in-Chief: Giuseppe Leone | Italy

2.3
Impact Factor 2025
3.2
CiteScore 2025
2.3
Impact Factor 2025
3.2
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

    Dimitar Efremov, Adrian Wiestner, Luca Laurenti
    e2012067
    2012-10-09
    https://doi.org/10.4084/mjhid.2012.067
    2735
    PDF: 937
    HTML: 9086
    Efremov 1: 288
    Efremov 2: 260
  • TYROSINE KINASE INHIBITORS AND INTERFERON

    Maria Dimou, Panagiotis Panagiotidis
    e2014006
    2014-01-02
    https://doi.org/10.4084/mjhid.2014.006
    3069
    PDF: 1551
    HTML: 3107
    Cover Letter: 284
  • MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

    Ibrahim C. Haznedaroglu
    e2014009
    2013-12-31
    https://doi.org/10.4084/mjhid.2014.009
    4253
    PDF: 1675
    HTML: 9334
    Untitled: 363
    Untitled: 239
    Untitled: 228
    Untitled: 245
    Untitled: 237
    Untitled: 408
  • BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

    Stefano Molica
    e2025053
    2025-06-29
    https://doi.org/10.4084/MJHID.2025.053
    1988
    PDF: 1090
    HTML: 486
  • SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

    Massimo Breccia, Giuliana Alimena
    e2014003
    2014-01-02
    https://doi.org/10.4084/mjhid.2014.003
    3463
    PDF: 1336
    HTML: 3564
  • TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

    Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti
    e2014005
    2014-01-02
    https://doi.org/10.4084/mjhid.2014.005
    3591
    PDF: 1706
    HTML: 4104
  • SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

    Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini
    e2021046
    2021-06-28
    https://doi.org/10.4084/MJHID.2021.046
    1599
    PDF: 824
    HTML: 510
  • TYROSINE KINASE INHIBITORS AND PREGNANCY

    Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti
    e2014028
    2014-04-07
    https://doi.org/10.4084/mjhid.2014.028
    3933
    PDF: 1822
    HTML: 2785
  • IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

    Tomasz Sacha
    e2014007
    2013-12-31
    https://doi.org/10.4084/mjhid.2014.007
    5256
    PDF: 3044
    HTML: 2389
  • THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

    Elvira Pelosi, Dr. Germana Castelli, Ugo Testa
    e2022080
    2022-10-29
    https://doi.org/10.4084/MJHID.2022.080
    1753
    PDF: 1318
    HTML: 661
  • BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

    Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli
    e2016011
    2016-02-10
    https://doi.org/10.4084/mjhid.2016.011
    4551
    PDF: 1595
    HTML: 3758
  • DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia

    Buket Altinok Gunes, Yalda Hekmatshoar, Tulin Ozkan, Sureyya Bozkurt, O.Sena Aydos, Yahya Buyukasik, Elifcan Aladag, Asuman Sunguroglu
    e2023008
    2023-01-01
    https://doi.org/10.4084/MJHID.2023.008
    1666
    PDF: 1362
    HTML: 548
  • DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

    Ibrahim C. Haznedaroglu
    e2015014
    2015-12-02
    https://doi.org/10.4084/mjhid.2015.014
    277961
    PDF: 1924
    HTML: 3920
  • GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey

    Mehmet Hilmi DOGU, Ali Irfan Emre TEKGUNDUZ, Burak DEVECI, Gulten KORKMAZ, Melda COMERT, Omur Gokmen SEVINDIK, Osman YOKUS, Istemi SERIN
    e2023031
    2023-04-28
    https://doi.org/10.4084/MJHID.2023.031
    1681
    PDF: 1003
    Suppl. Files: 503
    HTML: 313
  • Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.

    Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito, Elisa Buzzatti, Marco Lombardo, Massimo Cesareo, Adriano Venditti, Massimiliano Postorino, Maria Ilaria Del Principe
    e2026009
    2026-01-01
    https://doi.org/10.4084/MJHID.2026.009
    732
    PDF: 550
    Html: 328
  • TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

    Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo
    e2022040
    2022-04-28
    https://doi.org/10.4084/MJHID.2022.040
    2413
    PDF: 1721
    HTML: 765
  • OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

    Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien
    e2015003
    2015-01-01
    https://doi.org/10.4084/mjhid.2015.003
    2460
    PDF: 1145
    HTML: 2042
    Characteristic of study group: 280
  • EVOLVİNG PARADİGMS İN THE MANAGEMENT OF PRİMARY IMMUNE THROMBOCYTOPENİA İN ADULTS: FROM CORTİCOSTEROİDS TO TARGETED BİOLOGİC THERAPİES

    Massimo Martino, Laura Giordano, Maria Bruna Greve, Violetta Marafioti, Caterina Alati
    e2026067
    2026-09-01
    https://doi.org/10.4084/MJHID.2026.067
    404
    PDF: 380
    Html: 84
  • MOLECULAR MARKERS IN AML: PROGNOSTIC IMPLICATIONS AND IMPACT ON TREATMENT DECISION-MAKING

    Patrizia Chiusolo, Roberto Maggi, Angela Alessi, Simona Sica
    e2026087
    2026-10-31
    https://doi.org/10.4084/MJHID.2026.087
    127
    PDF: 79
    Html: 47
  • Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

    Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena
    e2016016
    2016-02-20
    https://doi.org/10.4084/mjhid.2016.016
    3064
    PDF: 770
    HTML: 1978
    figure 1: 249
    figure 2: 234
  • PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

    matteo molica, elisabetta abruzzese, massimo breccia
    e2020062
    2020-09-12
    https://doi.org/10.4084/mjhid.2020.062
    4405
    PDF: 1741
    HTML: 895
  • TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML

    Buket Altinok Gunes, Tulin OZKAN, Aynur Karadag Gurel, Semih Dalkilic, Nevin Belder, Zeynep Ozkeserli, Hilal Ozdag Sevgili, Meral Beksac, Nilgun Sayinalp, Abdullah Munci Yagci, Asuman Sunguroglu
    e2024058
    2024-06-29
    https://doi.org/10.4084/MJHID.2024.058
    1265
    PDF: 1265
    Suppl. Files: 610
    HTML: 117
  • First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience

    Dangui Chen
    e2026066
    2026-09-01
    https://doi.org/10.4084/MJHID.2026.066
    178
    PDF: 98
    Html: 61
  • THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association

    Katia Paciaroni, Selenia Campagna, Nicoletta Villiva', Enrico Maffini, Francesca Celesti, Attilio Tordi, Mariangela Lombardi, Giulia Dragonetti, Tommaso Caravita di Toritto
    e2025023
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.023
    1252
    PDF: 1334
    HTML: 150
  • Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

    Nathalia Sena de Oliveira Silva, Gislaine Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, Katia Borgia Barbosa Pagnano
    e2026001
    2026-01-01
    https://doi.org/10.4084/MJHID.2026.001
    913
    PDF: 641
    Html: 149
  • WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

    Michele Bibas, Shayna Sarosiek , Jorge Castillo
    e2025015
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.015
    2874
    PDF: 2229
    HTML: 952
  • OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES

    Jon Salmanton-Garcia, Francesco Marchesi, Oliver A. Cornely, Jannik Stemler, Pierantonio Menna
    e2026022
    2026-02-28
    https://doi.org/10.4084/MJHID.2026.022
    1971
    PDF: 2179
    Suppl. Files: 300
    HTML: 126
  • POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE

    Daniela Capello, Gianluca Gaidano
    e2009018
    https://doi.org/10.4084/mjhid.2009.018
    1483
    PDF: 514
    HTML: 18649
    Figure 1: 217
    Figure 2: 197
    Figure 3: 219
    Figure 4: 261
    Figure 5: 227
  • WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

    Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi
    e2018004
    2018-01-01
    https://doi.org/10.4084/mjhid.2018.004
    8020
    PDF: 2548
    HTML: 2184
    Table 1.: 290
    Table 2.: 312
    Table 3.: 275
    Table 4.: 281
  • “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

    Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin
    e2016047
    2016-10-15
    https://doi.org/10.4084/mjhid.2016.047
    4174
    PDF: 1154
    HTML: 3926
    Untitled: 210
    Cneo. Fig.1: 149
    Untitled: 141
    Untitled: 180
    Untitled: 181
  • NOVEL DRUGS IN FOLLICULAR LYMPHOMA

    Giuseppe Rossi, Antonella Anastasia
    e2016061
    2016-11-01
    https://doi.org/10.4084/mjhid.2016.061
    6027
    PDF: 1636
    HTML: 1690
    Untitled: 296
  • SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis

    Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Dr. Patrizia Bonadonna
    e2021068
    2021-10-29
    https://doi.org/10.4084/MJHID.2021.068
    1810
    PDF: 1176
    HTML: 527
  • NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms

    Gianfranco Catalano, Pasquale Niscola, Cristina Banella, Daniela Diverio, Malgorzata Monika Trawinska , Stefano Fratoni, Rita Iazzoni, Paolo de Fabritiis, Elisabetta abruzzese, Nelida Ines Noguera
    e2020083
    2020-10-27
    https://doi.org/10.4084/mjhid.2020.083
    1953
    PDF: 1284
    HTML: 376
  • VIRAL CIRRHOSIS: AN OVERVIEW OF HAEMOSTATIC ALTERATIONS AND CLINICAL CONSEQUENCES

    Francesca Romana Ponziani, Valerio De Stefano, Antonio Gasbarrini
    e2009033
    2009-12-29
    https://doi.org/10.4084/mjhid.2009.033
    2808
    PDF: 582
    HTML: 3639
  • INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

    Livio Pagano, Davide Facchinelli, Dr.
    e2018063
    2018-10-27
    https://doi.org/10.4084/mjhid.2018.063
    2230
    PDF: 1206
    HTML: 373
  • TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin

    Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni
    e2022073
    2022-10-29
    https://doi.org/10.4084/MJHID.2022.073
    1491
    PDF: 1151
    HTML: 493
  • WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

    Michele Bibas, Shayna Sarosiek, Jorge J. Castillo
    e2024061
    2024-06-29
    https://doi.org/10.4084/MJHID.2024.061
    3222
    PDF: 3451
    HTML: 817
  • TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

    Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi
    e2023038
    2023-06-29
    https://doi.org/10.4084/MJHID.2023.038
    2532
    PDF: 1959
    HTML: 1097
  • CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

    Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti
    e2024045
    2024-04-30
    https://doi.org/10.4084/MJHID.2024.045
    3973
    PDF: 1754
    HTML: 120
  • Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a real world setting

    Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà
    e2026013
    2026-01-01
    https://doi.org/10.4084/MJHID.2026.013
    731
    PDF: 600
    Html: 115
  • Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review

    Toshifumi Takahashi
    e2020005
    2020-01-01
    https://doi.org/10.4084/mjhid.2020.005
    2020
    PDF: 1355
    HTML: 394
  • SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA

    Naveen Gupta, Manoranjan Mahapatra, Tulika Seth, Seema Tyagi, Sudha Sazawal, Renu Saxena
    e2021004
    2021-01-01
    https://doi.org/10.4084/mjhid.2021.004
    2375
    PDF: 693
    HTML: 336
  • Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature

    Jayastu Senapati, Anup J Devasia, Abhijeet Ganapule, Leni George, Auro Viswabandya
    e2014016
    2014-02-17
    https://doi.org/10.4084/mjhid.2014.016
    2173
    PDF: 1041
    HTML: 1798
    Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated AML- IMAGES: 246
  • Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review

    Domenico Santorsola, Elisabetta Abruzzese
    e2015020
    2015-02-12
    https://doi.org/10.4084/mjhid.2015.020
    2194
    PDF: 1310
    HTML: 1681
  • OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

    Mohamed Amine BEKADJA
    e2017062
    2017-10-25
    https://doi.org/10.4084/mjhid.2017.062
    3078
    PDF: 823
    HTML: 952
  • IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?

    Federica Sorà, Patrizia Chiusolo, Francesco autore, Sabrina Giammarco, luca laurenti, elisabetta metafuni, idanna innocenti, eugenio galli, andrea bacigalupo, simona sica
    e2021062
    2021-10-29
    https://doi.org/10.4084/MJHID.2021.062
    1434
    PDF: 600
    HTML: 227
  • Zanubrutinib as upfront treatment in de-novo B-cell prolymphocytic leukemia: the case of two elderlies.

    Silvia Giorgi, Giovanna Leonardi, Monica Maccaferri, Elena Sbadili, Carlo Caterina, Giovanni Fera, Ambra Paolini, Leonardo Potenza, Anna Candoni, Mario Luppi, Roberto Marasca
    e2025061
    2025-08-31
    https://doi.org/10.4084/MJHID.2025.061
    1472
    PDF: 682
    Html: 386
  • Isavuconazole therapy of disseminated and encephalic Saprochaete capitata infection in an acute myeloid leukemia patient treated with midostaurin.

    Salvatore Perrone, Chiara Lisi, Elettra Ortu La Barbera, Cristina Luise, Miriam Lichtner, Corrado Girmenia, Giuseppe Cimino
    e2020026
    2020-04-27
    https://doi.org/10.4084/mjhid.2020.026
    1721
    PDF: 908
    HTML: 420
  • AUTOLOGOUS STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA STILL A VALID TREATMENT OPTION, OR IS THE GAME OVER ?

    Fabienne McClanahan, Peter Dreger
    e2012071
    2012-11-06
    https://doi.org/10.4084/mjhid.2012.071
    2666
    PDF: 908
    HTML: 1793
  • BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

    Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo
    e2024070
    2024-08-31
    https://doi.org/10.4084/MJHID.2024.070
    1845
    PDF: 1181
    HTML: 201
1 - 50 of 74 items 1 2 > >> 
Make a Submission

Links

  • Editorial Board
  • Alert me!
  • Advertising
  • Scopus
  • DOAJ
  • Article Processing Charge

Information

  • For Readers
  • For Authors
  • For Librarians

Indexing

  • OpenAlex
  • Analytics

PubMed

MJHID CiteScore by Scopus

Clarivate Analytics

this journal is covered
by Clarivate Analytics

 

The Mediterranean Journal of Hematology and Infectious Diseases has been selected for coverage in Clarivate Analytics products and services. Beginning with V. 7 (1) 2015.

AskBisht

Indexed in AskBisht.com

Facebook

FOLLOW US

MJHID in EuroPub Database

EuroPub

CLL UpDate

Keywords

Mediterranean Journal of Hematology and Infectious Diseases

is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. The MJHID is indexed and abstracted in Science Citation Index Expanded and Journal Citation Reports/InCites beginning with V. 7 (1) 2015.

eISSN: 2035-3006

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission

Our App Is Free For Anyone!

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.